Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II VacSYn trial.

IoT helps to decentralise clinical trials while providing pharmaceutical companies with a higher return on investment.

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results ...

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...

Antag Therapeutics has commenced a first-in-human, double-blind Phase Ia trial of the GIPR antagonist, AT-7687, intended for ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, DM-101PX.

Patient engagement through advisory boards, surveys, and listening sessions can help address industry challenges like trial delays.

Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with ...